Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This case report details a 47-year-old female with atopic dermatitis who developed alopecia areata after six months on dupilumab therapy; treatment discontinuation and other interventions led to complete hair regrowth, suggesting dupilumab may trigger alopecia areata in patients with atopic or autoimmune predispositions.

This review highlights new treatment options for alopecia, including JAK inhibitors and Wnt pathway-targeting therapies, which may offer better efficacy and safety than traditional treatments like minoxidil and finasteride, but notes the need for more research on long-term effects and patient-specific responses.

This review examines lesser-known factors contributing to polycystic ovarian syndrome and reports no new clinical results, emphasizing the need for further research into individualized treatment and prevention strategies.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

This study concluded that advancements in understanding the immunological mechanisms of alopecia areata have led to promising therapies, particularly JAK inhibitors and novel drug delivery systems, but further research is needed for clinical application.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

This review examined 40 studies on exosome-based therapies for alopecia areata, reporting significant hair regrowth and improvements in hair count, length, and thickness, but highlighted the need for standardized methodologies and robust RCTs before clinical application.

In this study, researchers identified three proteins, DEFB1, HGFAC, and CYB5D2, as potential drug targets for alopecia areata, and suggested that the traditional Chinese medicine ingredient cimigenol shows promise in interacting with DEFB1 for potential treatment.

This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.

This review discusses the latest findings presented at the 4th Intercontinental Meeting of Hair Research Societies, covering advances in hair follicle biology, genetic bases for hair disorders, and potential new therapeutic approaches, but it reports no original study results.

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

This review explores how exosomes can be used therapeutically in autoimmune skin diseases, emphasizing that their properties like stability and biocompatibility make them promising for targeting immune signaling pathways involved in conditions such as inflammation and scleroderma.

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

In this review, researchers discussed the anti-inflammatory and immunomodulatory properties of metformin and hypothesized that its topical application could benefit those with alopecia areata, given its effects on immune pathways, hair regrowth, and autoimmune disease management.

This review discusses the similar immune pathways and genetic risk factors of vitiligo and alopecia areata but reports no new clinical findings, emphasizing the potential for shared treatment research.

In this study, researchers found that cytokine dysregulation linked to genetic background is present in both patients and healthy but genetically related individuals in two autoimmune skin diseases, Pemphigus vulgaris and Alopecia areata, suggesting that protective immune mechanisms may prevent disease manifestation in predisposed individuals.

This review discusses the role of the complement pathway in alopecia areata and reports no new clinical results; the authors suggest that targeting this pathway could offer treatment options.